Wuhan YZY Biopharma Co., Ltd. (HKG:2496)
Hong Kong · Delayed Price · Currency is HKD 4.000
0.00 (0.00%)
At close: Nov 2, 2026
Wuhan YZY Biopharma Revenue
Wuhan YZY Biopharma had revenue of 35.77M CNY in the half year ending June 30, 2026, with 1,161.42% growth. This brings the company's total for the last twelve months to 58.26M, down -60.99% year-over-year. In the year 2025, Wuhan YZY Biopharma had annual revenue of 66.86M, down -37.99%. That makes Wuhan YZY Biopharma the 38,049th largest company in the world by revenue and 2,318th in Hong Kong.
Revenue (ttm)
58.26M CNY
Revenue Growth
-60.99%
P/S Ratio
11.53
Revenue / Employee
856.81K CNY
Employees
68
Market Cap
775.40M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.86M | -40.95M | -37.99% |
| Dec 31, 2024 | 107.81M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.28M | -9.89M | -81.28% |
| Dec 31, 2021 | 12.16M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.50B |
| 3D Medicines | 412.66M |
| JW (Cayman) Therapeutics Co. | 333.25M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 170.32M |
| Kintor Pharmaceutical | 90.90M |
| CANbridge Pharmaceuticals | 64.28M |
| Zhaoke Ophthalmology | 40.41M |
| Brii Biosciences | 40.23M |
Wuhan YZY Biopharma News
- 2 months ago - Wuhan YZY Biopharma Quarterly report: H1 2026 - Filings
- 2 months ago - Wuhan YZY Biopharma Earnings release: H1 2026 - Filings
- 7 months ago - Wuhan YZY Biopharma Earnings release: H2 2025 - Filings
- 7 months ago - Wuhan YZY Biopharma Annual report: H2 2025 - Filings